Abrocitinib Expanded Access Protocol in Adolescents and Adults With Moderate to Severe Atopic Dermatitis

Inclusion Criteria: * 12 years of age or older * Clinical diagnosis of chronic atopic dermatitis for at least 6 months * Inadequate treatment options with available, approved medicated topical and systemic therapies for moderate to severe atopic dermatitis * Moderate to severe atopic dermatitis as indicated by at least one of the following: IGA ≥3; EASI ≥16 * Not eligible for participation in any ongoing clinical trial of abrocitinib, including lack of access due to geographical limitations Exclusion Criteria: * Medical, psychiatric, or laboratory abnormality that may increase the risk associated with study participation * Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, malignancies, current or history of certain infections, lymphoproliferative disorders and other medical conditions at the discretion of the investigator * Require treatment with prohibited medications during the study * Discontinued prior treatment with any systemic JAK inhibitor due to safety or tolerability issues * 12 to \<18 years old without documented evidence of having received at least one dose of the varicella vaccine or without evidence of prior exposure to varicella zoster virus based on serological test * Pregnant or breastfeeding women or women of childbearing potential who are sexually active and unwilling to use contraception